Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.45 |
| ▸ | SLC2A2 | P11168 | 3/20 | 0.45 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.45 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 7/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309176 | 0.86 | CYP11B2 (0.40) | SLC2A1SLC2A2SLC2A3SLC2A4CYP11B2 | |
| SCHEMBL3089383 | 0.83 | AR (0.44) | SLC2A1SLC2A2SLC2A3SLC2A4CYP11B2 | |
| SCHEMBL3083312 | 0.81 | AR (0.46) | CYP11B2ARCRHR1CYP11B1 | |
| SCHEMBL3076763 | 0.79 | AR (0.49) | SLC2A1SLC2A2SLC2A3CYP11B2AR | |
| SCHEMBL3085330 | 0.79 | AR (0.50) | SLC2A1CYP11B2ARCNR1GAA | |
| SCHEMBL3088592 | 0.78 | AR (0.50) | SLC2A1SLC2A2SLC2A3CYP11B2AR | |
| SCHEMBL3069283 | 0.77 | CYP11B2 (0.41) | CYP11B2ARCRHR1CNR1GAA | |
| SCHEMBL3080496 | 0.75 | AR (0.50) | CYP11B2ARCNR1CYP11B1 | |
| SCHEMBL3086576 | 0.74 | AR (0.53) | CYP11B2ARCRHR1CYP11B1 | |
| SCHEMBL3075829 | 0.74 | AR (0.44) | CYP11B2ARCRHR1CNR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | SLC2A1 3366/4885SLC2A2 3658/4885SLC2A3 3131/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | SLC2A1 3345/4885SLC2A2 3629/4885SLC2A3 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.